Skip header and navigation

37 records – page 1 of 4.

Document Type
Evidence Search Report
Review Code
EOC011901-01 ESR
Question Submitted
January 19, 2021
Date Completed
January 21, 2021
Status
3. Completed
Research Team
EOC
potential recipients of the covid vaccine are refusing vaccination (both HCW and citizens). What
Document Type
Evidence Search Report
Review Code
EOC011901-01 ESR
Question Submitted
January 19, 2021
Date Completed
January 21, 2021
Status
3. Completed
Research Team
EOC
Category
Infection Prevention and Control
Subject
Vaccination
Risk
Infection Prevention and Control
Population
All adults
Clinical Setting
Community
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Mueller, M.; Young, C. How safe are the Pfizer and Moderna vaccinations? 2021 Jan 21; Document no.: EOC011901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 31 p. (CEST evidence search report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC011901 RR
Question Submitted
January 19, 2021
Date Completed
January 24, 2021
Status
3. Completed
Research Team
EOC
vaccine that are refusing vaccination (both HCW and citizens). Purpose We try to investigate
Document Type
Rapid Review
Review Code
EOC011901 RR
Question Submitted
January 19, 2021
Date Completed
January 24, 2021
Status
3. Completed
Research Team
EOC
Key Findings
Initial findings from RCTs of the two authorized COVID-19 vaccines (Pfizer-BioNTech and Moderna) reported that the vaccines are safe. However, subsequent reports show that the adverse and severe allergic reactions to these vaccines are higher than the general rates for vaccines.
Various regulatory agencies identify the risk for serious allergic reactions as low for the authorized vaccines, and they continue to monitor the vaccines’ safety closely.
Further investigations to make causal relationships with reported severe allergic reactions or deaths are needed.
Risks and benefits of receiving the vaccines should be discussed individually in vulnerable populations including pregnant or breast-feeding women, immunocompromised people, or frail elderly people.
Category
Infection Prevention and Control
Subject
Vaccination
Risk
Infection Prevention and Control
Population
All adults
Clinical Setting
Community
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Azizian, A; Groot, G; Mueller, M; Young, C. How safe are the Pfizer and Moderna vaccinations? 2021 Jan 24; Document no.: EOC011901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 30 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC220501 ESR
Question Submitted
May 3, 2022
Date Completed
May 4, 2022
Status
3. Completed
Research Team
EOC
the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? Context: When
Document Type
Evidence Search Report
Review Code
EOC220501 ESR
Question Submitted
May 3, 2022
Date Completed
May 4, 2022
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Subject
Decision Making
Infection Prevention and Control
Vaccination
Priority Level
Level 1 2-3 days
Cite As
Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 04. Document no.: EOC220501 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 12 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC220501 RR Table
Question Submitted
May 3, 2022
Date Completed
May 10, 2022
Status
3. Completed
Research Team
EOC
-19 vaccination? Review Code: EOC220501 RR Table Version: 1 Review Date: May 10, 2022 Review
Document Type
Table
Review Code
EOC220501 RR Table
Question Submitted
May 3, 2022
Date Completed
May 10, 2022
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Subject
Decision Making
Infection Prevention and Control
Vaccination
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 10, Document no.: EOC220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

EOC220501 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
EOC220501 RR
Question Submitted
May 3, 2022
Date Completed
May 10, 2022
Status
3. Completed
Research Team
EOC
intervention therapeutic products and COVID-19 vaccination? Review Code: EOC220501 RR Review Date
Document Type
Rapid Review
Review Code
EOC220501 RR
Question Submitted
May 3, 2022
Date Completed
May 10, 2022
Status
3. Completed
Research Team
EOC
Key Findings
Recommendations for COVID-19 vaccination timing following monoclonal antibody or convalescent plasma therapy range from a precautionary 90 day deferral, to assessing on a case-by-case basis to no need for deferral
Only published evidence is a sub-study of the larger Bamlanivimab trial where prophylactic administration of Bamlanivimab prior to mRNA COVID-19 vaccination did not affect the immune response regardless of age, risk category or vaccine product used
No evidence currently exists for vaccination timing following the use of antiviral products such as Paxlovid or Remdesivir
Category
Clinical Management
Subject
Decision Making
Infection Prevention and Control
Vaccination
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 10, Document no.: EOC220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 10 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC220102 RR Table
Question Submitted
January 10, 2022
Date Completed
February 4, 2022
Status
4. Update in progress
Research Team
EOC
Vaccination: A Guide to Booster Vaccination for Individuals Aged 18 Years and Over and Those Aged 16 Years
Document Type
Table
Review Code
EOC220102 RR Table
Question Submitted
January 10, 2022
Date Completed
February 4, 2022
Status
4. Update in progress
Research Team
EOC
Category
Epidemiology
Infection Prevention and Control
Subject
Immunity
Infection Prevention and Control
Pediatrics
Public Health
Vaccination
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Reeder, B; Groot, G; Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive an mRNA vaccine booster/3rd dose? 2022 Feb 04, Document no.: EOC220102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

EOC220102 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
EOC220102 RR
Question Submitted
January 10, 2022
Date Completed
February 4, 2022
Status
4. Update in progress
Research Team
EOC
, the vaccination campaign including 12-17 year olds is still underway to provide the primary 2-dose series
Document Type
Rapid Review
Review Code
EOC220102 RR
Question Submitted
January 10, 2022
Date Completed
February 4, 2022
Status
4. Update in progress
Research Team
EOC
Key Findings
The CDC has released a recommendation that all adolescents 12-17 be offered booster vaccines using only the Pfizer COVID-19 vaccine, at least 5 months following the primary series
The CDC guidelines follow the review of unpublished Israeli data of 12-15 year olds vaccinated 5-6 months prior showing an equivalent infection rate to unvaccinated, and that those who receive boosters are at about 1/3 of the risk
Health Canada has not yet approved booster doses for general use in 12-17 year olds, however NACI has recommended that boosters, at least 6 months following the primary series, should be considered for the following groups within that age group o Those with an underlying medical condition at high risk of severe illness due to COVID-19 (including those who are immunocompromised and received a 3-dose primary series) o Those who are residents in congregate settings (e.g. shelters, group homes, quarters for migrant workers, correctional facilities) o Those who belong to racialized and/or marginalized communities disproportionately affected by COVID-19
Category
Epidemiology
Infection Prevention and Control
Subject
Immunity
Infection Prevention and Control
Pediatrics
Public Health
Vaccination
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Reeder, B; Groot, G; Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive the booster to increase their immunity? 2022 Feb 04, Document no.: EOC220102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 8 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC220102v002 ESR
Question Submitted
January 10, 2022
Date Completed
April 6, 2022
Status
4. Update in progress
Research Team
EOC
]. https://www.cdc.gov/mmwr/volumes/71/wr/mm7109e2.htm  Alroy-Preis, S. 12-15 y/o Booster Vaccination
Document Type
Evidence Search Report
Review Code
EOC220102v002 ESR
Question Submitted
January 10, 2022
Date Completed
April 6, 2022
Status
4. Update in progress
Research Team
EOC
Notes
Updated review not currently planned.
Category
Epidemiology
Infection Prevention and Control
Subject
Immunity
Infection Prevention and Control
Pediatrics
Public Health
Vaccination
Priority Level
Level 2 One week (7 days)
Cite As
Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive the booster to increase their immunity? 2022 Apr 06, Document no.: EOC220102v002 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 11 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC220301 SBAR
Question Submitted
March 1, 2022
Date Completed
May 2022
Status
3. Completed
Research Team
EOC
of the approach for COVID-19 vaccination specifically, in a multi-site study across Canada, as well
Document Type
Rapid Review
Review Code
EOC220301 SBAR
Question Submitted
March 1, 2022
Date Completed
May 2022
Status
3. Completed
Research Team
EOC
Notes
This is not a regular rapid review. It was decided to write this SBAR instead.
Category
Healthcare Services
Subject
Vaccines
Vaccination
Public Health
Decision Making
Health Personnel
Infection Prevention and Control
Population
All
Clinical Setting
Community
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Rowein S, Singh S, Habbick M, Mehdiyeva K, Miller L, Gagneur, A, Groot G, Neudorf C, Camillo CA, Tokhmafshan, F, Muhajarine N. Motivational Interviewing for Vaccine Hesitancy. May 2022. Document no.: [12.1]. CoVaRR-Net Public Health, Health Systems, Social Policy Team, c2022.
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC210502 RR
Question Submitted
May 27, 2021
Date Completed
June 10, 2021
Status
3. Completed
Research Team
EOC
. Key Findings June 11, 2021  Only agreed upon contraindications against COVID-19 vaccination
Document Type
Rapid Review
Review Code
EOC210502 RR
Question Submitted
May 27, 2021
Date Completed
June 10, 2021
Status
3. Completed
Research Team
EOC
Key Findings
Only agreed upon contraindications against COVID-19 vaccination is for individuals with a history of allergic reactions to a component of the vaccine or an allergic reaction to a previous dose
Where allergies to components exist, vaccination with an alternative COVID-19 vaccine should be considered
Autoimmune conditions and treatments are not considered contraindications, however timing of vaccines in relation to treatment regimens should be considered
Category
Administration
Subject
Vaccination
Decision Making
Risk
Population
All
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Groot, G; Reeder, B; Young, C; Ellsworth, C. What are legitimate exemptions/contraindications for COVID-19 vaccines from a medical point of view? 2021 Jun 10, Document no.: EOC210502 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 8 p. (CEST rapid review report).
Related Documents
Documents
Less detail

37 records – page 1 of 4.